A new dosing paradigm: High-dose, short-course therapy for community-acquired pneumonia

Clinical Cornerstone

Volumn 6, Issue SPEC. ISS APR., 2004, Pages 21-28

  File Jr , Thomas M ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BENZATHINE PENICILLIN; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CIPROFLOXACIN; LEVOFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CELL LEVEL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HUMAN; NONHUMAN; SHORT COURSE THERAPY; SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 3042511955     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Mandell LA, File TM Jr. Short-course treatment of community-acquired pneumonia. Clin Infect Dis. 2003;37:761-763.
2. World Health Organization. Overcoming antimicrobial resistance. Available at: www.who.int/infectious-disease-report. Accessed October 9, 2003.
3. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-382.
4. Mandell LA, Marrie TJ, Grossman RF, et al. Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can Respir J. 2000;7:371-382.
5. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax. 2001;56(Suppl 4):IV1-IV64.
6. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2001; 163:1730-1754.
7. Andremont A. The future control of bacterial resistance to antimicrobial agents. Am J Infect Control. 2001;29:256-258.
8. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998;279: 365-370.
9. Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA. 2001;286:49-56.
10. Pankuch GA, Jacobs MR, Appelbaum PC. MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother. 1996;40:2071-2074.
11. Visalli MA, Jacobs MR, Appelbaum PC. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother. 1996;40:362-366.
12. Visalli MA, Jacobs MR, Appelbaum PC. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. Diagn Microbiol Infect Dis. 1997;28:131-137.
13. Spangler SK, Jacobs MR, Appelbaum PC. Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other beta-lactams. J Antimicrob Chemother. 1997;39:141-148.
14. Croisier D, Chavanet P, Lequeu C, et al. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother. 2002;50: 349-360.
15. Bunn PA Jr, McDermott W, Hadley SJ, et al. Treatment of pneumoccocal pneumonia with penicillin. JAMA. 1945;129:320-327.
16. Montravers P, Fagon JY, Chastre J, et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis. 1993; 147:38-44.
17. Cecil RL, McDermott W, eds. Textbook of Medicine. 7th ed. Philadelphia, Pa: WB Saunders Company; 1948:128.
18. Harrison TR, Resnick WR, Wintrobe MM, et al, eds. Principles of Internal Medicine. 5th ed. New York, NY: McGraw-Hill; 1967:1509.
19. Witt RL, Hamburger M. The nature and treatment of pneumococcal pneumonia. Med Clin North Am. 1963;47:1257-1270.
20. Awunor-Renner C. Length of antibiotic therapy in in-patients with primary pneumonias. Ann Trop Med Parasitol. 1979;73:235-240.
21. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279:1452-1457.
22. Hoepelman IM, Mollers MJ, van Schie MH, et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on longterm outcome. Int J Antimicrob Agents. 1997;9: 141-146.
23. Socan M. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J Chemother. 1998;10:64-68.
24. O'Doherty B, Muller O, and the Azithromycin Study Group. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1998;17:828-833.
25. Schönwald S, Kuzman I, Oreskovic K, et al. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome - a randomized study. Infection. 1999;27:198-202.
26. Tellier G, Isakov T, Peterman W, et al. Efficacy and safety of telithromycin (800 mg once daily) for 5 or 7 days vs. clarithromycin (500 mg twice daily) for 10 days in the treatment of patients with community-acquired pneumonia. Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego, California. Abstract L-373.
27. Saravolatz L, Manzor O, Check C, et al. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother. 2001;47:875-877.
28. 0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J Antimicrob Chemother. 2003;51:905-911.
29. Chien S-C, Wong FA, Fowler CL, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother. 1998;42:885-888.
30. Gotfried MHM, Danziger LHP, Rodvold KAP. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest. 2001;119:1114-1122.
31. Lister PD. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2002;44:43-49.
32. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003;37:752-760. Available at: http://www.journals.uchicago.edu/CID/journal/rapid.html.
33. Tennenberg AM. High-dose, short-course levofloxacin 750 mg vs. standard regimen for community-acquired pneumonia. Presented at: The 99th American Thoracic Society International Conference; May 16, 2003; Seattle, Wash. Abstract 2452.